Publication of Annual Financial Report

Medica Group PLC

28 April 2023

 

28 April 2023

Medica Group Plc

Publication of Annual Report

Medica Group Plc (LSE:MGP, the "Company"), the UK market leader by revenue in the provision of teleradiology services, today announces that the Company's annual report and accounts (Annual Report) for the year ended 31 December 2022, is now available on the Company's website at:

www.medicagroupplc.com/investors/results-and-reports.

Th Annual Report will be posted to those shareholders who have opted out of electronic communications shortly.

A copy of the Annual Report will also be submitted to the National Storage Mechanism and will be available for inspection in due course at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism 

Notice of the Company's 2023 Annual General Meeting (AGM) will be posted to shareholders and available on the Company's website in May, and accordingly the Company will publish a further announcement at that time.

or further information, please contact:

Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer	[phone]
FTI Consulting Victoria Foster Mitchell Sam Purewal	[phone]
Liberum (Joint Broker) Phil Walker Richard Lindley	[phone]
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown	[phone]

About Medica Group PLC

Medica (LSE:MGP) is an international provider of high-quality telemedicine services. It is the market leader in teleradiology in the UK and Ireland, working with more than 100 NHS Trusts and HSE hospitals in Ireland, in addition to private hospitals, insurance groups and diagnostic imaging companies. Its network of consultant radiologists, radiographers and specialist doctors interpret and report MRI, CT, ultrasound and X-ray images on behalf of healthcare providers, using Medica's bespoke, secure technology platform for fast and responsive delivery. The company's core services include NightHawk, an urgent, out-of-hours offering available to clients 24/7 with dedicated pathways for stroke and major trauma, and Elective, for routine reporting.

In Ireland, Medica carries out patient scanning, as well as reporting, and runs a diabetic retinopathy screening programme for the National Screening Service. Through its US business, RadMD, Medica provides global pharmaceutical and biotech companies, as well as contract research organisations with specialist imaging services for clinical trials. 

For more information, please visit: www.medicagroupplc.com 

 

END